Cross-presentation in viral immunity and self-tolerance

Nature Reviews Immunology

Volumn 1, Issue 2, 2001, Pages 126-134

  Heath, William R ^a   Carbone, Francis R ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ANIMAL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BIOLOGICAL MODEL; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; REVIEW; T LYMPHOCYTE; VIRUS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MODELS, IMMUNOLOGICAL; SELF TOLERANCE; T-LYMPHOCYTES; VIRUSES;

EID: 0035525290     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/35100512     Document Type: Review

References (83)

1. Miller, B. J., Appel, M. C., O'Neil, J. J. & Wicker, L. S. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J. Immunol. 140, 52-58 (1988).
2. Bendelac, A., Carnaud, C., Boitard, C. & Bach, J. F. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J. Exp. Med. 166, 823-832 (1987).
3. + T cells. J. Exp. Med. 186, 239-245 (1997). Provides evidence that self-antigens can be cross-presented and that this leads to deletional tolerance.
4. Schonrich, G. et al. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 65, 293-304 (1991).
5. Schonrich, G. et al. Tolerance induction as a multi-step process. Eur. J. Immunol. 24, 285-293 (1994).
6. Oldstone, M. B., Nerenberg, M., Southern, P., Price, J. & Lewicki, H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65, 319-331 (1991).
7. Ohashi, P. S. et al. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65, 305-317 (1991).
8. + T-helper and a T-killer cell. Nature 393, 474-478 (1998).
9. Bennett, S. R. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
10. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
11. Salio, M., Cella, M., Suter, M. & Lanzavecchia, A. Inhibition of dendritic cell maturation by herpes simplex virus. Eur. J. Immunol. 29, 3245-3253 (1999).
12. Servet-Delprat, C. et al. Measles virus induces abnormal differentiation of CD40 ligand-activated human dendritic cells. J. Immunol. 164, 1753-1760 (2000).
13. Fugier-Vivier, I. et al. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J. Exp. Med. 186, 813-823 (1997).
14. Gabrilovich, D. I. et al. Murine retrovirus induces defects in the function of dendritic cells at early stages of infection. Cell Immunol. 158, 167-181 (1994).
15. Ignatius, R. et al. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J. Virol. 74, 11329-11338 (2000).
16. Engelmayer, J. et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163, 6762-6768 (1999).
17. Sevilla, N. et al. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 192, 1249-1260 (2000).
18. Bevan, M. J. Antigen recognition. Class discrimination in the world of immunology. Nature 325, 192-194 (1987).
19. Bevan, M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143, 1283-1288 (1976).
20. - DCs can cross-present when exposed to lipopolysaccharide.
21. + dendritic cells cross-present cell-associated antigens.
22. Huang, A. Y. et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965 (1994).
23. + T cell help. J. Exp. Med. 186, 65-70 (1997).
24. Norbury, C. C., Chambers, B. J., Prescott, A. R., Ljunggren, H. G. & Watts, C. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur. J. Immunol. 27, 280-288 (1997).
25. Regnault, A. et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189, 371-380 (1999).
26. Ke, Y. & Kapp, J. A. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake. J. Exp. Med. 184, 1179-1184 (1996).
27. Rock, K. L., Gamble, S. & Rothstein, L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249, 918-921 (1990).
28. Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B. & Rock, K. L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl Acad. Sci. USA 90, 4942-4946 (1993).
29. Albert, M. L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
30. Heath, W. R. & Carbone, F. R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19, 47-64 (2001).
31. Carbone, F. R. & Bevan, M. J. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J. Exp. Med. 171, 377-387 (1990).
32. Vremec, D. et al. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J. Exp. Med. 176, 47-58 (1992).
33. Kurts, C., Cannarile, M., Klebba, I. & Brocker, T. Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J. Immunol. 166, 1439-1442 (2001).
34. Yewdell, J. W., Norbury, C. C. & Bennink, J. R. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73, 1-77 (1999).
35. Yewdell, J. W., Bennink, J. R. & Hosaka, Y. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 239, 637-640 (1988).
36. Finelli, A. et al. MHC class I restricted T cell responses to Listeria monocytogenes, an intracellular bacterial pathogen. Immunol. Res. 19, 211-223 (1999).
37. Schirmbeck, R., Melber, K. & Reimann, J. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. Eur. J. Immunol. 25, 1063-1070 (1995).
38. Bachmann, M. F. et al. TAP1-independent loading of class I molecules by exogenous viral proteins. Eur. J. Immunol. 25, 1739-1743 (1995).
39. Harding, C. V. & Song, R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 153, 4925-4933 (1994).
40. Srivastava, P. K., Udono, H., Blachere, N. E. & Li, Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39, 93-98 (1994).
41. Wolfers, J. et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nature Med. 7, 297-303 (2001).
42. Zitvogel, L. et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med. 4, 594-600 (1998).
43. + cytotoxic T lymphocytes. J. Exp. Med. 191, 541-550 (2000).
44. Huang, A. Y., Bruce, A. T., Pardoll, D. M. & Levitsky, H. I. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 4, 349-355 (1996).
45. Kurts, C. et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184, 923-930 (1996). First paper to report cross-presentation of tissue antigens and showed this process is constitutive.
46. Sigal, L. J., Crotty, S., Andino, R. & Rock, K. L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398, 77-80 (1999). First paper to provide direct evidence that CTL immunity to viruses could be induced by cross-priming.
47. Kurts, C., Miller, J. F., Subramaniam, R. M., Carbone, F. R. & Heath, W. R. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188, 409-414 (1998). Provides the important observation that antigen dose is vital to whether a tissue antigen will be cross-presented. Also shows that tissue damage enhances cross-presentaton.
48. Bellone, M. et al. Processing of engulfed apoptotic bodies yields T cell epitopes. J. Immunol. 159, 5391-5399 (1997).
49. - T cells by dendritic cells. J. Virol. 74, 10018-10024 (2000).
50. Debrick, J. E., Campbell, P. A. & Staerz, U. D. Macrophages as accessory cells for class I MHC-restricted immune responses. J. Immunol. 147, 2846-2851 (1991).
51. Huang, F. P. et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J. Exp. Med. 191, 435-444 (2000). Shows that gut-associated dendritic cells constitutively capture apoptotic epithelial cells and transport them to the mesenteric lymph node.
52. + T-cell tolerance by cross-presentation of self antigens. Immunol. Rev. 165, 267-277 (1998).
53. Kurts, C. et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl Acad. Sci. USA 96, 12703-12707 (1999).
54. + T cell tolerance to peripherally expressed antigens. J. Immunol. 163, 723-727 (1999).
55. Li, M. et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J. Immunol. 166, 6099-6103 (2001).
56. Harshyne, L. A., Watkins, S. C., Gambotto, A. & Barratt-Boyes, S. M. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J. Immunol. 166, 3717-3723 (2001). First paper to show that dendritic cells might capture and cross-present antigens from other cells without killing the donor cells.
57. von Boehmer, H. & Hafen, K. Minor but not major histocompatibility antigens of thymus epithelium tolerize precursors of cytolytic T cells. Nature 320, 626-628 (1986).
58. Merkenschlager, M., Power, M. O., Pircher, H. & Fisher, A. G. Intrathymic deletion of MHC class I-restricted cytotoxic T cell precursors by constitutive cross-presentation of exogenous antigen. Eur. J. Immunol. 29, 1477-1486 (1999).
59. + T cell tolerance to parenchymal self antigens requires presentation by bone marrow derived antigen presenting cells. J. Exp. Med. 187, 1555-1564 (1998).
60. Forster, I. & Lieberam, I. Peripheral tolerance of CD4 T cells following local activation in adolescent mice. Eur. J. Immunol. 26, 3194-3202 (1996).
61. Hoglund, P. et al. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J. Exp. Med. 189, 331-339 (1999).
62. Morgan, D. J. et al. Ontogeny of T cell tolerance to peripherally expressed antigens. Proc. Natl Acad. Sci. USA 96, 3854-3858 (1999).
63. Gooding, L. R. & Edwards, C. B. H-2 antigen requirements in the in vitro induction of SV40-specific cytotoxic T lymphocytes. J. Immunol. 124, 1258-1262 (1980).
64. Schoenberger, S. P. et al. Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells. J. Immunol. 161, 3808-3812 (1998).
65. Sigal, L. J. & Rock, K. L. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J. Exp. Med. 192, 1143-1150 (2000).
66. Lenz, L. L., Butz, E. A. & Bevan, M. J. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens. J. Exp. Med. 192, 1135-1142 (2000).
67. + T cells in vivo. J. Immunol. 166, 4355-4362 (2001).
68. Tindle, R. W. & Frazer, I. H. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr. Top. Microbiol. Immunol. 186, 217-253 (1994).
69. Tortorella, D., Gewurz, B. E., Furman, M. H., Schust, D. J. & Ploegh, H. L. Viral subversion of the immune system. Annu. Rev. Immunol. 18, 861-926 (2000).
70. Hill, A. et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 375, 411-415 (1995).
71. Ahn, K. et al. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc. Natl Acad. Sci. USA 93, 10990-10995 (1996).
72. Fruh, K. et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 375, 415-418 (1995).
73. Gilbert, M. J., Riddell, S. R., Plachter, B. & Greenberg, P. D. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383, 720-722 (1996).
74. Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. & Masucci, M. G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl Acad. Sci. USA 94, 12616-12621 (1997).
75. Paabo, S. et al. Adenovirus proteins and MHC expression. Adv. Cancer Res. 52, 151-163 (1989).
76. Ronchetti, A. et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J. Immunol. 163, 130-136 (1999).
77. Chiodoni, C. et al. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med. 190, 125-133 (1999).
78. Kundig, T. M. et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268, 1343-1347 (1995).
79. Ochsenbein, A. F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064 (2001).
80. Vremec, D., Pooley, J., Hochrein, H., Wu, L. & Shortman, K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164, 2978-2986 (2000).
81. Kamath, A. T. et al. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J. Immunol. 165, 6762-6770 (2000).
82. De Smedt, T. et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med. 184, 1413-1424 (1996).
83. Pulendran, B. et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J. Immunol. 159, 2222-2231 (1997).